- Emergence of the SARS-CoV-2 B.1.1.7 lineage and its characteristics at an outpatient
- 2 testing site in Berlin, Germany, January-March 2021
- Welmoed van Loon¹, Heike Rössig², Susen Burock³, Jörg Hofmann⁴, Julian Bernhardt¹,
- 5 Elizabeth Linzbach¹, Domenika Pettenkofer¹, Christian Schönfeld¹, Maximilian Gertler¹,
- 6 Joachim Seybold², Tobias Kurth⁵, Frank P. Mockenhaupt¹
- 8 1 Institute of Tropical Medicine and International Health, Charité Universitätsmedizin
- 9 Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin,
- 10 Berlin, Germany

3

7

- 2 Medical Directorate, Charité Universitätsmedizin Berlin, corporate member of Freie
- Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- 13 3 Charité Comprehensive Cancer Center, Charité Universitätsmedizin Berlin, corporate
- member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- 4 Labor Berlin Charité Vivantes GmbH, Berlin, Germany
- 5 Institute of Public Health, Charité-Universitätsmedizin Berlin, corporate member of Freie
- 17 Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- 19 Corresponding author: Welmoed van Loon, welmoed.van-loon@charite.de
- 21 Abstract

18

- Within five weeks in early 2021, B.1.1.7 became the dominant SARS-CoV-2 lineage at an
- outpatient testing site in Berlin. Characteristics including Ct-values of 193 and 125 recently ill
- outpatients with B.1.1.7 and wildtype virus, respectively, were similar, except for more
- commonly reported sore throat and travel, and less frequently stated loss of smell and taste in
- the former.

The SARS-CoV-2 B.1.1.7 lineage (variant of concern [VOC] 202012/01, or 20I/501Y.V1) 27 likely emerged during autumn 2020 in the United Kingdom and quickly became the dominant 28 strain (1). It carries multiple mutations and deletions, including 501Y and deletion 29 $\Delta H69/\Delta V70$ (del69–70) in the spike protein. The B.1.1.7 variant is considered to exhibit 30 increased transmissibility compared to non-VOC lineages (1), hereafter referred to as 31 wildtype virus, whereas increased fatality is ambiguous (2,3). 32 At the outpatient SARS-CoV-2 testing site of Charité - Universitätsmedizin Berlin, the 33 first patient infected with the B.1.1.7 variant was identified on January 18, 2021. Herein, we 34 describe lineage prevalence over time as well as demographic and clinical characteristics in 35 outpatients with the B.1.1.7 variant and those with the wildtype virus presenting until end of 36 March. Ethical approval for the analysis was obtained from Charité's institutional review 37 board (EA4/083/20). 38 39 The study 40 41 Details of the testing site have been described (4). Upon presentation, physicians interviewed patients on demographics, medical history, and symptoms. If indicated, an combined oro-42 nasopharyngeal swab was collected. SARS-CoV-2 infection was assessed applying a cobas® 43 6800/8800 analyzer (Roche Diagnostics, Mannheim, Germany), targeting both ORF1ab and E 44 Gene (5). All positive samples were typed for the N501Y and del69–70 polymorphisms by 45 melting curve analysis. Variants including both polymorphisms were considered B.1.1.7. 46 Between January 18 and March 29, 2021, 349 SARS-CoV-2 positive patients 47 presented. In this period, the proportion of the B.1.1.7 variant increased from 2% to >90% 48 (Figure 1). In total, 35.8% (125/349) of the samples belonged to the wildtype lineage, 57.0% 49 (199/349) were the B.1.1.7 variant, and 7.2% (25/349) other non-wildtype variants (non-50 VOCs). 51 Six patients previously had received ≥1 SARS-CoV-2 vaccination (five, first dose 52 AZD1222 [Oxford-AstraZeneca] 4-24 days before; one, second BNT162b2 53 54 [Pfizer/BioNTech] dose 66 days before); all were infected with B.1.1.7 and were excluded from analysis as were patients carrying lineages other than wildtype or B.1.1.7. Half of the 55 patients were female (49%); mean age was 36±15 years. Almost all reported symptoms 56 (97%). Median symptom duration until testing was 3 days (IQR, 2, 4). Leading complaints 57 were fatigue (72%), headache (69%), and muscle ache (60%). Fifteen percent reported travel 58

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

outside of Berlin in the last fourteen days, and half (49%) had had contact with a confirmed SARS-CoV-2 case (Table 1). Most assessed characteristics did not substantially differ between patients carrying the SARS-CoV-2 wildtype or the B.1.1.7 lineage, including age, sex, leading complaints, symptom duration, contacts to a confirmed case, and time passed since such contacts (Table 1). However, B.1.1.7 patients had travelled more frequently than those infected with the wildtype strain (19% vs. 10%). As for symptoms, patients with B.1.1.7 more often reported sore throat than those with the wildtype lineage (54% vs. 42%) but less often loss of smell/taste (24% vs. 38%) (Table 1). We observed no difference in cycle threshold (Ct)-values for the E Gene target between B.1.1.7 and wildtype samples (medians, 20.2 vs. 20.1) (Table 1). In patients reporting a symptom duration of ≥ 7 days, Ct-values appeared to be lower for the B.1.1.7 lineage (median, 26.2; wildtype, 30.1; Mann-Whitney-U-test, P=0.7) (Table 1, Figure 2). Lastly, we explored which combination of variables in our dataset best predicted the B.1.1.7 variant in a logistic regression applying a backward stepwise selection based on the Akaike information criterion. This identified the best set of predictors as absent loss of smell/taste (P=0.01), longer symptom duration (P=0.02), sore throat (P=0.05), lower Ctvalue (P=0.07), travel in the last 14 days (P=0.08), lower age (P=0.09), and absent rhinorrhea (P=0.12). We then used bootstrap technique to repeat the variable selection in 1,000 replicated datasets and evaluated how often these variables were selected with the backward selection. This resulted in loss of smell/taste, 89%; symptom duration, 78%; travel, 73%; sore throat, 68%; Ct-value, 66%; age, 56%; rhinorrhea, 51%. Absent loss of smell/taste, longer symptom duration, and travel were selected most often, indicating their importance in B.1.1.7 variant prediction. All analyses were done in R version 3.6.3. **Discussion** The first B.1.1.7 case in Germany was notified in late December 2020 (6). At our testing site, the B.1.1.7 lineage was first observed three weeks later and replaced the wildtype virus as the dominant strain within five weeks only. The rapid emergence and dominance of this lineage likely results from its increased transmissibility (1), which is potentially caused by spike protein polymorphisms including 501Y conferring enhanced mucosal binding (7); 681H, near a region important for transmission (8); deletion 69-70, linked to immune escape (9). Viral replication in vitro does not differ from pre-existing strains (10).

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

The B.1.1.7 variant reportedly is associated with increased mortality (2), although this has been questioned (3). In our young outpatient study population, we did not observe major, lineage-dependent differences in leading symptoms. Nevertheless, loss of smell/taste, among the most specific COVID-19 symptoms (4), was less common in patients infected with B.1.1.7., whereas, sore throat was more frequently reported than in wildtype virus patients. Similarly, a UK survey revealed less loss of smell/taste in B.1.1.7 patients but more sore throat, cough, fatigue, myalgia, and fever (11). In contrast, no associations between SARS-CoV-2 B.1.1.7 and self-reported symptoms, disease duration, or hospital admissions were seen in another UK study (12). The most important factors for B.1.1.7 infection prediction in our study appeared to be loss of smell/taste and longer symptom duration, in addition to recent travel. As for Ct-values, one study observed similar figures in patients infected with B.1.1.7 and wildtype lineages; however, a longer duration of infection with the B.1.1.7 variant was suggestive by repeated sampling over time (13). Likewise, longer persistence has been observed for B.1.1.7 (14), but also lower Ct-values (higher viral load) compared to wildtype samples. Lower Ct-values were also seen in other studies on population (15) and inpatient levels (3). In our cross-sectional assessment of recently ill outpatients, we did not observe such differences. Still, increased transmissibility may result from the variant's prolonged excretion (13,14). Test timing appears crucial for the interpretation of Ct-values. Outpatients are commonly tested earlier in the course of infection than inpatients. The combination of prolonged viral shedding with different test timing might explain increased viral load in B.1.1.7 samples in inpatients, but not in recently ill outpatients. In support of that, in our outpatients with ≥ 7 days symptom duration, Ct-values in B.1.1.7 samples were suggestively reduced. However, the comparison groups were small. Our data enable to detect a maximum effect size on overall Ct-values, which corresponds to B.1.1.7 Ct-values being 1.5 units below wildtype, or 1.0 above. The main limitation in our study are limited subgroup sizes, which reduced the likelihood to detect differences between rare characteristics. Others are the one-time assessment, subjective symptom duration, and the variable manifestation of SARS-CoV-2 infection (4). Strengths include standardized procedures conducted by trained medical staff and the prospective nature of the study evaluating patient groups during the same time period, reducing the likelihood of confounding due to temporal effects.

SARS-CoV-2 VOC B.1.1.7 is now the dominant lineage in Berlin. On the outpatient level, there appears to be no major difference in clinical manifestation.

Acknowledgments

We thank the Corona Untersuchungsstelle (CUS) staff at the Charité - Universitaetsmedizin Berlin for their dedication and hard work during the COVID-19 pandemic.

References 131 1. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Hopkins S, et al. 132 Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from 133 linking epidemiological and genetic data. MedRxiv [Preprint]. 2021 [cited 2021 134 Apr 1]. Available from: 135 https://www.medrxiv.org/content/10.1101/2020.12.30.20249034v2. 136 2. Davies NG, Jarvis CI, CMMID COVID-19 Working Group, Edmunds WJ, 137 Jewell NP, Diaz-Ordaz K, et al. Increased mortality in community-tested cases 138 139 of SARS-CoV-2 lineage B.1.1.7. Nature. 2021 Mar 15;1–5. doi: 140 10.1038/s41586-021-03426-1. Frampton D, Rampling T, Cross A, Bailey H, Heaney J, Byott M, et al. Genomic 141 3. characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage 142 143 in London, UK: a whole-genome sequencing and hospital-based cohort study. Lancet Infect Dis. 2021 Apr 12;0(0). doi: 10.1016/S1473-3099(21)00170-5. 144 145 4. Maechler F, Gertler M, Hermes J, van Loon W, Schwab F, Piening B, et al. Epidemiological and clinical characteristics of SARS-CoV-2 infections at a 146 testing site in Berlin, Germany, March and April 2020—a cross-sectional study. 147 Clin Microbiol Infect. 2020 Dec;26(12):1685.e7-1685.e12. doi: 148 10.1016/j.cmi.2020.08.017. 149 5. Poljak M, Korva M, Gašper NK, Komloš KF, Sagadin M, Uršič T, et al. Clinical 150 evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch 151 during 48 hours in the midst of the COVID-19 pandemic. J Clin Microbiol. 2020 152 May 26;58(6):e00599-20. doi: 10.1128/JCM.00599-20. 153 6. Robert Koch Institute. Coronavirus Disease 2019 (COVID-19) Daily Situation 154 Report of the Robert Koch Institute. 26/12/2020. 2020. Available from: 155 https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberi 156 chte/Dez_2020/2020-12-26-en.pdf?__blob=publicationFile 157 7. Chan KK, Tan TJC, Narayanan KK, Procko E. An engineered decoy receptor for 158 SARS-CoV-2 broadly binds protein S sequence variants. Sci Adv. 2021 Feb 159 17;7(8):eabf1738. doi: 10.1126/sciadv.abf1738. 160 8. Peacock TP, Goldhill DH, Zhou J, Baillon L, Frise R, Swann OC, et al. The 161 furin cleavage site of SARS-CoV-2 spike protein is a key determinant for 162 transmission due to enhanced replication in airway cells. BioRxiv [Preprint]; 163

2020 [cited 2021 Apr 14]. Available from: 164 https://doi.org/10.1101/2020.09.30.318311. 165 9. Kemp SA, Collier DA, Datir R, Ferreira IATM, Gayed S, Jahun A, et al. 166 Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation. Nature. 167 2021 Apr;592(7853):277-282. doi: 10.1038/s41586-021-03291-y. 168 10. Brown JC, Goldhill DH, Zhou J, Peacock TP, Frise R, Goonawardane N, et al. 169 Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is 170 not accounted for by a replicative advantage in primary airway cells or antibody 171 172 escape. BioRxiv [Preprint]. 2021 [cited 2021 Apr 3]; Available from: https://doi.org/10.1101/2021.02.24.432576. 173 174 11. Office for National Statistics. Coronavirus (COVID-19) Infection Survey: characteristics of people testing positive for COVID-19 in England. 2021. 175 176 Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/co 177 178 nditions and diseases / articles / corona virus covid 19 in fections in the community in engl and/characteristicsofpeopletestingpositiveforcovid19inengland27january2021 179 180 12. Graham MS, Sudre CH, May AM, Antonelli M, Murray B, Varsavsky T, et al. Changes in symptomatology, re-infection and transmissibility associated with 181 SARS-CoV-2 variant B.1.1.7: an ecological study The COVID-19 Genomics 182 UK (COG-UK) consortium. MedRxiv [Preprint]. 2021 [cited 2021 Apr 1]; 183 Available from: 184 https://www.medrxiv.org/content/10.1101/2021.01.28.21250680v2. 185 13. Kissler SM, Fauver JR, Mack C, Tai CG, Watkins AE, Samant RM, et al. 186 Densely sampled viral trajectories suggest longer duration of acute infection 187 with B.1.1.7 1 variant relative to non-B.1.1.7 SARS-CoV-2 2 3. MedRxiv 188 [Preprint]. 2021 [cited 2021 Mar 30]; Available from: 189 https://doi.org/10.1101/2021.02.16.21251535. 190 191 14. Calistri P, Amato L, Puglia I, Cito F, Di Giuseppe A, Danzetta ML, et al. Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by 192 longer persistence and higher viral RNA loads in nasopharyngeal swabs. Int J 193 Infect Dis. 2021 Mar 5;105:753-755. doi: 10.1016/j.ijid.2021.03.005. 194 Kidd M, Richter A, Best A, Cumley N, Mirza J, Percival B, et al. S-variant 195 15. SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in 196

samples tested by ThermoFisher TaqPath RT-qPCR. J Infect Dis. 2021 Feb 13:jiab082. doi: 10.1093/infdis/jiab082.

Table 1. Characteristics of SARS-CoV-2 positive outpatients attending the Charité testing site, separated by wildtype and B.1.1.7 lineages

| | Wildtype lineage | B.1.1.7 variant | OR [95%CI], difference in mean [95%CI], or difference in median [95%CI]* |
|---|--|--|--|
| | N=125 | N=193 | |
| | (%, mean [SD], or median [25 th , 75 th quantile]) | (%, mean [SD], or median [25 th , 75 th quantile]) | |
| Female | 44.8% | 51.0% | 1.3 (0.8, 2.0) |
| Age, years | 36.6 (13.8) | 34.8 (15.9) | 1.8 (-1.5, 5.1) |
| Any symptoms | 97.6% | 96.4% | 0.7 (0.2, 2.6) |
| Self-reported fever in the last 48 hours | 38.4% | 42.5% | 1.2 (0.8, 1.9) |
| Temperature in case of fever (°C, by patient statement) | 38.3 (0.6) | 38.2 (0.7) | 0.1 (-0.2, 0.4) |
| Short of breath | 9.6% | 13.5% | 1.5 (0.7, 3.0) |
| Fatigue | 73.6% | 71.5% | 0.9 (0.5, 1.5) |
| Pain on the chest | 2.4% | 1.0% | 0.4 (0.1, 2.6) |
| Diarrhea | 15.2% | 12.4% | 0.8 (0.4, 1.5) |
| Loss of smell/taste | 37.6% | 23.8% | 0.5 (0.3, 0.9) |
| Muscle ache | 60.0% | 60.1% | 1.0 (0.6, 1.6) |
| Sore throat | 41.6% | 53.9% | 1.6 (1.0, 2.6) |
| Cough | 48.8% | 50.8% | 1.1 (0.7, 1.7) |
| Headache | 68.8% | 68.9% | 1.0 (0.6, 1.6) |
| Chills | 35.2% | 34.7% | 1.0 (0.6, 1.6) |
| Rhinorrhea | 60.8% | 52.8% | 0.7 (0.5, 1.1) |
| Symptom duration upon test (days) | 3.0 (2.0, 4.8) | 3.0 (2.0, 4.0) | 0.0 (-1.0, 0.0) |
| Contact to a confirmed SARS-CoV-2 case | 48.0% | 50.3% | 1.1 (0.7, 1.7) |
| Time between contact to a confirmed SARS-CoV-2 case and test (days) | 4.0 (1.2, 7.0) | 4.0 (1.0, 6.0) | 0.0 (-1.5, 3.0) |
| Traveled outside the | 9.6% | 18.7% | 2.2 (1.1, 4.3) |

| | Wildtype lineage | B.1.1.7 variant | OR [95%CI], difference in mean |
|-----------------------------------|--|--|--------------------------------|
| | N=125 | N=193 | [95%CI], or difference in |
| | (%, mean [SD], or median [25 th , 75 th quantile]) | (%, mean [SD], or median [25 th , 75 th quantile]) | median [95%CI]* |
| Berlin region in the last 14 days | | | |
| Ct-value | 20.2 (17.4, 24.1) | 20.1 (17.1, 22.8) | 0.1 (-0.9, 1.6) |
| Symptom duration < 7 days | N=113; 19.9 (17.4, 23.5) | N =171; 19.5 (16.6, 22.6) | 0.4 (-1.0, 1.7) |
| Symptom duration ≥ 7 days | N=6; 30.1 (26.1, 31.3) | N=11; 26.2 (21.4, 31.2) | 3.9 (-5.6, 10.0) |

^{*} The 95% confidence interval for the difference in medians was computed by a percentile bootstrap with 1,000 replications.




Figure 1. Proportion of SARS-CoV-2 lineages at the Charité testing site, 2021. The numbers on top of the bars indicate the total number of positive SARS-CoV-2-tests assessed. Six (partially) vaccinated outpatients are included for completeness. Note that calendar week 13 only includes one day (March 29).




Figure 2. Comparison of median Ct-values in SARS-CoV-2 wildtype and B.1.1.7 lineage, by symptom duration. The boxplots indicate medians, 25^{th} and 75^{th} percentiles (i.e., Q1 and Q3). The upper whiskers reach the largest value with a maximum Q3 + 1.5 * interquartile range (IQR). The lower whiskers reach the smallest value with a minimum Q1 - 1.5 * IQR. The numbers on top of the boxplots indicate the total number of observations included in the comparison.